Norvancomycin monohydrochloride is a cell wall synthesis inhibitor, targeting peptidoglycan precursors of Gram-positive bacteria. It irreversibly inhibits bacterial cell wall synthesis, showing antibacterial activity. Primarily used for Gram-positive bacterial infections like MRSA and MRSE, it can also be incorporated into bionic calcium phosphate coatings on titanium implants to enhance antibacterial activity and prevent postoperative orthopedic infections.
- Targets peptidoglycan precursors of Gram-positive bacteria
- Cannot pass the blood-brain barrier
- Inhibits bacterial cell wall synthesis
- Effective against Gram-positive bacterial infections (MRSA, MRSE)
- Enhances antibacterial activity in titanium implant coatings
- Inhibits Staphylococcus aureus in in vitro studies
- Widely distributed in rat tissues (not in brain)